Under the terms of the partnership, ICQ Consultants will provide consulting and engineering services for the installation, maintenance, qualification, and support of Yokogawa's bioreactor systems and related products in the US.
Yokogawa Electric Corporation, a Japanese electrical engineering and software company, and Integrated Commissioning and Qualification Consultants (ICQ Consultants), a US-based biotechnology company, announced on Feb. 24, 2021 that they have entered into a partnership through which ICQ Consultants will provide consulting and engineering services for the installation, maintenance, qualification, and support of Yokogawa's bioreactor systems and related products in the US.
Through the collaboration, Yokogawa will gain access to ICQ Consultants’ engineering and laboratory expertise in the biopharmaceutical market to launch its bioprocess technologies in the US, Yokogawa said in a company press release. Yokogawa’s first portfolio product from the partnership is the Advanced Control Bioreactor System BR1000. Released on Jan. 8, 2021, the new system works to automate lab-scale mammalian cell culture with real-time monitoring and advanced process control.
"We are very excited to join Yokogawa in this strategic partnership agreement to help facilitate the support of their bioreactor systems and related products throughout the United States,” said Michael Bogan, president of ICQ Consultants, in the press release. “As ICQ Consultants continues to expand operations across the country, we are poised to further develop lasting relationships, which has been a key factor in our ongoing success. I look forward to working with Yokogawa on this unique and collaborative opportunity.”
“Alliances with industry experts like ICQ Consultants are vital to gain expertise and penetration in the high growth biopharmaceutical market,” added Hiroshi Nakao, a Yokogawa vice president and head of the company's Life Innovation Business Headquarters, in the press release. “ICQ Consultants’ engineering and technical knowledge in drug manufacturing will support our innovative new bioreactor and bioprocess technologies and help position Yokogawa for rapid sales and market leadership in the emerging bio-industrial autonomy sector."
Source: Yokogawa
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.